Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval

30m zacks
Roche Holding AG (RHHBY - Free Report) announced that the FDA has approved the Lucentis 0.3 mg prefilled syringe (“PFS”) as a new method of administering medicine for all forms of diabetic retinopathy. (88-0)

GSK's bid in focus as Reckitt quits Pfizer consumer health auction

6h channelnewsasia
Reckitt Benckiser Group said on Wednesday it ended discussions with Pfizer Inc over buying its consumer healthcare business. (26-0)

Regeneron Eylea Hits 24-Week Primary Endpoint in Study

2018-03-20 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced positive topline results from the phase III study evaluating Eylea (aflibercept) Injection in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME), compared with sham injection. (53-0)

Unum Therapeutics Updates Proposed IPO Terms

2018-03-20 seekingalpha
UNUM's lead candidate is facing dosage limiting challenges and the firm is still very early stage. (6-0)

Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-3)

JF's Core Biotech Buys Edition 1 Volume 7: Updates And Taking Advantage Of Current Weakness

2018-03-20 seekingalpha
The biotech sector has been a weak performer lately after several bits of bad news came including a clinical hold for Solid Biosciences. (552-3)

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

2018-03-20 globenewswire
Basel, March 20, 2018 Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies. (6-0)

Is Novartis (NVS) a Suitable Stock for Value Investors Now?

2018-03-19 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. (8-0)

Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?

2018-03-19 zacks
It has been about a month since the last earnings report for Incyte Corporation (INCY - Free Report) . Shares have added about 5.2% in that time frame. (49-0)

ETF Month #4: Developed Markets (Ex-North America) With EFA. But Is There A Better Alternative?

2018-03-18 seekingalpha
During "ETF Month", I plan to survey a number of ETFs that have a lot of followers on Seeking Alpha, but for some reason don't have much coverage on the site. Hopefully, this will improve the visibility of Cambridge Income Laboratory and draw more members to our service, allowing me to make the newsletter better than ever. I will also be taking ETF suggestions, so do let me know if you have any ETFs on your horizon. (29-0)

resTOR Bio: Stimulating Immune Responses In Elderly Populations

2018-03-16 seekingalpha
resTORbio (TORC) entered the public forum with their recent IPO on Jan 26th with a offering price of $15 for 5.7 million shares. They opened at $18.62 and have wobbled between $16 and $18.50 since on a 10-day average volume of 117,000 shares, with shares most recently trading in the $14.50 range. The company's lead product, RTB101, focuses on modulating and improving the immune system in elder populations, whose immune systems have declined. (6-1)

Why Multiple Sclerosis is a Promising but Risky Space?

2018-03-16 zacks
The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen (BIIB - Free Report) and partner AbbVie’s (ABBV - Free Report) decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Both companies decided to withdraw the drug on grounds of the complex and evolving benefit/risk profile of Zinbryta, given the limited number of patients treated. (177-0)

The 10 Best Stocks to Invest In Right Now

2018-03-15 investorplace
It’s a different market than it was just two months ago. Volatility has returned, even if it remains modest relative to historical levels. Big names like Procter & Gamble Co (NYSE:PG) and Walmart Inc (NYSE:WMT), among others, have seen precipitous share price declines just in the past few weeks. (564-1)

IDEAYA Biosciences Nabs $94 Million

2018-03-15 biospace
Two years after securing $46 million in financing from the likes of Celgene and Novartis AG, South San Francisco-based IDEAYA Biosciences has completed another successful fundraising round with support from GV (formerly Google Ventures) and Roche Venture Fund. (62-1)

Updating Our Thoughts On Celgene

2018-03-14 seekingalpha
The combination of disruptive new discoveries coupled with burgeoning demand thanks to the aging demographics of the world’s population sets the biotech space for a potential virtuous long-term cycle. (184-0)

CUSIP: 66987V109